FDA, schizophrenia
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
FDA Approves Potentially Groundbreaking Schizophrenia Drug
People living with schizophrenia will soon have a new and potentially groundbreaking treatment available. It’s called Cobenfy, and it’s the first new drug for the mental health condition to be ...
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral medication that is manufactured by Bristol Myers Squibb in New Jersey.
FDA Approves the First New Schizophrenia Drug in Decades
26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder. Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb ...
FDA approves new type of schizophrenia drug
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
FDA Approves First New Schizophrenia Drug In 30 Years: Cobenfy Offers Hope With Fewer Side Effects | Details
The FDA has approved Cobenfy, the first new schizophrenia treatment in 30 years, offering a novel approach with fewer side effects. Developed by Karuna Therapeutics, the drug is set to provide new hope for patients.
FDA Approves the First New Type of Schizophrenia Drug in Decades
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle movement, and sedation — that can cause patients to discontinue treatment.
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical company.
FDA Approves Revolutionary Schizophrenia Drug
In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name Cobenfy,
Yahoo4d
FDA approves 1st new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, ...
Becker's Hospital Review3d
FDA approves schizophrenia treatment
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
Coventry Telegraph4d
Man arrested for sending 'sexual messages' to 14-year-old child in Coventry
A man has been arrested on suspicion of sending sexual messages to a child in Coventry. He was detained in Walsgrave on Monday (September 23). Officers arrested the 39-year-old man, who has not ...
The Washington Post4d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione, director of FDA’s division of psychiatry, said in a statement. “This approval offers a ...
FDA’s new mandate shifts what patients should know about breast density
Mammogram providers are now federally required to tell their patients about their breast density. The new U.S. Food and Drug ...